Module 5: Treatment of Imatinib Resistant Chronic Myelogenous Leukemia
This learning activity has been designated for 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
After completing this educational activity, the learner should be better able to:
- Describe the mechanisms of imatinib resistance in chronic myelogenous leukemia (CML)
- Explain BCR-ABL–independent resistance
- State the data supporting roles for dasatinib and nilotinib in managing imatinib-resistant CML
- Determine an alternative course of action in patients who have developed resistance to imatinib
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module